Evidence map›Paper›PMID 39120657›Full record

ReviewThe European journal of health economics : HEPAC : health economics in prevention and care2025

A critical review of the use of R

Wynand P M M van de Ven, Richard C van Kleef

Abstract readReview
In one paragraph

Review in The European journal of health economics : HEPAC : health economics in prevention and care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Ex ante evaluation of risk adjustment models for prospective provider payment: a conceptual framework and empirical application.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  2. Differentiation of morbidity measurement in Germany's morbidity-based risk adjustment depending on general practitioner and specialist treatment.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  3. Article
  4. Pharmacy cost groups for the German morbidity-based risk compensation scheme.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Wynand P M M van de VenErasmus University Rotterdam / Erasmus Centre for Health Economics Rotterdam (EsCHER), Rotterdam, The Netherlands. vandeven@eshpm.eur.nl.ORCID http://orcid.org/0000-0001-9076-3308
Richard C van KleefErasmus University Rotterdam / Erasmus Centre for Health Economics Rotterdam (EsCHER), Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nearly all empirical studies that estimate the coefficients of a risk equalization formula present the value of the statistical measure R

Indexed as

Models, StatisticalRisk AdjustmentCumming’s prediction measure (CPM)Health insuranceMean absolute prediction error (MAPE)Payment system fit (PSF)R2Risk equalization

Identifiers

PMID39120657
PMCPMC11937047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.